Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641768 | 0.93 | EGLN3 (0.74) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| SCHEMBL12727318 | 0.93 | EGLN3 (0.74) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| SCHEMBL1641831 | 0.90 | EGLN3 (0.58) | EGLN3MEN1KMT2AEGLN1EGLN2 | |
| SCHEMBL12727430 | 0.89 | EGLN3 (0.76) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| SCHEMBL12727427 | 0.89 | EGLN3 (0.71) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| SCHEMBL1641912 | 0.89 | EGLN3 (0.71) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| SCHEMBL12727518 | 0.88 | EGLN3 (0.56) | EGLN3MEN1KMT2AEGLN1EGLN2 | |
| SCHEMBL12727431 | 0.88 | EGLN3 (0.67) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| SCHEMBL1642088 | 0.88 | EGLN3 (0.70) | EGLN3MEN1KMT2ANPC1EGLN1 | |
| Ammonia Solution, Strong SCHEMBL1640329 | 0.87 | EGLN3 (0.69) | EGLN3MEN1KMT2ANPC1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885MEN1 3669/4885KMT2A 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.